Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cingulate Inc. CING
$1.03
-$0.01 (-0.96%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
12961914.00000000
-
week52high
2.00
-
week52low
0.66
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-1.54000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 04:00
Описание компании
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Laidlaw & Co. | Buy | 20 янв 2022 г. | |
| Aegis Capital | Buy | 11 янв 2022 г. | |
| Maxim Group | Buy | 22 ноя 2022 г. | |
| HC Wainwright & Co. | Buy | 17 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Silva Raul R. | A | 16084 | 16084 | 30 дек 2022 г. |
| Schaffer Shane J. | A | 70738 | 200 | 16 дек 2022 г. |
| Schaffer Shane J. | A | 41500 | 10000 | 16 дек 2022 г. |
| Schaffer Shane J. | A | 70538 | 3642 | 15 дек 2022 г. |
| Callahan Jennifer L. | A | 34508 | 7548 | 14 дек 2022 г. |
| Schaffer Shane J. | A | 31500 | 13267 | 14 дек 2022 г. |
| Werth Peter J. | A | 975165 | 28934 | 13 дек 2022 г. |
| Schaffer Shane J. | A | 66896 | 396 | 13 дек 2022 г. |
| Schaffer Shane J. | A | 18233 | 1733 | 13 дек 2022 г. |
| Callahan Jennifer L. | A | 26960 | 1530 | 29 ноя 2022 г. |
Новостная лента
Cingulate Inc. to Present at Investor Summit Group's Q4 Conference
Newsfile Corp
03 ноя 2022 г. в 07:00
Kansas City, Kansas--(Newsfile Corp. - November 3, 2022) - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Shane Schaffer, CEO, and Tom Dalton, Vice President of IR & PR, will present a company overview at the Q4 Investor Summit live in New York City at the Sheraton Times Square.
Cingulate to Present at LD Micro Investor Conference
GlobeNewsWire
20 окт 2022 г. в 14:20
KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022.
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational
GlobeNewsWire
17 июн 2022 г. в 12:45
KANSAS CITY, Kan., June 17, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, will present a company overview at the Diamond Equity Research 2022 Virtual Emerging Growth Invitational on Thursday, June 23, 2022 at 1:40 PM EST. Following the presentation, Dr. Schaffer will take questions from participants.
Cingulate to Present at H.C. Wainwright Global Investment Conference
GlobeNewsWire
18 мая 2022 г. в 17:20
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and Chief Executive Officer, Shane J. Schaffer, and Chief Medical Officer, Matthew Brams, M.D., will present a company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, from 3:00-3:30 p.m. ET, at the Fontainebleau Miami Beach Hotel, Miami, FL.
Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder Studies
Benzinga
08 февр 2022 г. в 12:20
Cingulate Inc CING plans to initiate Phase 3 studies for CTx-1301 for Attention Deficit/Hyperactivity Disorder (ADHD) in 2022. Get the Inside Access Traders Are Using to Profit More and Win Bigger.